Skip to main content

Table 3 Results of virological and genotypic resistance testing by cohort, Arua, Uganda, 2006

From: Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda

 

M12 cohort

(N = 59)

M24 cohort

(N = 27)

HIV RNA < 400 copies/mL (%; 95% CI)

35 (59.3; 46.1-71.3)

9 (33.3; 17.5-54.0)

HIV RNA 400-999 copies/mL (%; 95% CI)

7 (11.9; 5.6-23.3)

1 (3.7; 0.5-24.5)

HIV RNA ≥ 1,000 copies/mL (%; 95% CI)

17 (28.8; 18.5-42.0)

17 (62.9; 42.5-79.7)

   Available genotypic resistance (%)

17 (100)

17 (100)

   Wild type virus (%)

3 (17.6)

1 (5.9)

   Resistance to ≥ 1 ARV drug (%)

13 (76.5)

16 (94.1)

   Resistance to EFV and NVP (%)

0 (0)

0 (0)

   Resistance to 3TC, EFV and NVP (%)

12 (70.6)

6 (35.3)

   Extensive resistancea (%)

0 (0)

8 (47.1)

  1. Note: ARV, antiretroviral; 95% CI, binomial 95% confidence interval; EFV, efavirenz; NVP, nevirapine; 3TC, lamivudine.
  2. aResistance to EFV, NVP, 3TC, stavudine, zidovudine or tenofovir and didanosine.